FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:419-421 July 31, 2003 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Yang, J. C. PubMed Citation

Early in the 20th century, it was hypothesized that solid tumors secrete factors, now referred to as angiogenic factors, that induce angiogenesis — the formation of new blood vessels — thereby ensuring the delivery of enough blood to support the growth of the tumor. The idea that inhibiting angiogenesis would have an antitumor effect has been borne out by the startling anticancer activity of some antiangiogenic agents in tumor-bearing mice. For these reasons, perhaps no area of cancer research has attracted as much attention, both on Main Street and on Wall Street, as angiogenesis.

Unfortunately, the dramatic effects of antiangiogenic . . . [Full Text of this Article]

Source Information

From the Dana–Farber Cancer Institute, Boston.

This article has been cited by other articles:

• Kusmartsev, S., Eruslanov, E., Kubler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., Siemann, D., Vieweg, J. (2008). Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma. J. Immunol. 181: 346-353 [Abstract] [Full Text]  
• Miyauchi, Y., Kato, M., Tokunaga, F., Iwai, K. (2008). The COP9/Signalosome Increases the Efficiency of von Hippel-Lindau Protein Ubiquitin Ligase-mediated Hypoxia-inducible Factor-{alpha} Ubiquitination. J. Biol. Chem. 283: 16622-16631 [Abstract] [Full Text]  
• Wu, K. L., Miao, H., Khan, S. (2007). JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism. Am. J. Physiol. Renal Physiol. 293: F1836-F1846 [Abstract] [Full Text]  
• Parton, M., Gore, M., Eisen, T. (2006). Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer. JCO 24: 5584-5592 [Abstract] [Full Text]  
• Schoffski, P., Dumez, H., Clement, P., Hoeben, A., Prenen, H., Wolter, P., Joniau, S., Roskams, T., Van Poppel, H. (2006). Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17: 1185-1196 [Abstract] [Full Text]  
• Tzukerman, M., Rosenberg, T., Reiter, I., Ben-Eliezer, S., Denkberg, G., Coleman, R., Reiter, Y., Skorecki, K. (2006). The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts.. Cancer Res. 66: 3792-3801 [Abstract] [Full Text]  
• Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., Rini, B. I. (2006). Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 16-24 [Abstract] [Full Text]  
• Mestas, J., Burdick, M. D., Reckamp, K., Pantuck, A., Figlin, R. A., Strieter, R. M. (2005). The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma. J. Immunol. 175: 5351-5357 [Abstract] [Full Text]  
• Mani, A., Gelmann, E. P. (2005). The Ubiquitin-Proteasome Pathway and Its Role in Cancer. JCO 23: 4776-4789 [Abstract] [Full Text]  
• Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M. A., Melamed, J., Semenza, G. L. (2005). Stromal Cell-Derived Factor-1{alpha} and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor. Cancer Res. 65: 6178-6188 [Abstract] [Full Text]  
• Megumi, Y., Miyauchi, Y., Sakurai, H., Nobeyama, H., Lorick, K., Nakamura, E., Chiba, T., Tanaka, K., Weissman, A. M., Kirisako, T., Ogawa, O., Iwai, K. (2005). Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex. GENES CELLS 10: 679-691 [Abstract] [Full Text]  
• Semenza, G. L. (2005). Involvement of hypoxia-inductible factor 1 in preinvasive and early-stage cancer. aacrmtg 2005: 1459-1460 [Abstract]  
• Amato, R. J. (2005). Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15 [Abstract] [Full Text]  
• Kaelin, W. G. Jr. (2004). The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer. Clin. Cancer Res. 10: 6290S-6295S [Abstract] [Full Text]  
• Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., Slamon, D. J. (2004). Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development. Clin. Cancer Res. 10: 3885-3896 [Full Text]  
• Semenza, G. L. (2004). Overexpression of hypoxia-inducible factor 1 in human cancers: Mechanisms and consequences.. aacrmtg 2004: 1312-1313 [Abstract]